TScan Therapeutics GAAP EPS of -$0.25, revenue of $1.04M Nov. 12, 2024 9:48 AM ET By: Urvi Shah , SA News Editor [Seeking Alpha]
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: Seeking Alpha
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology Seeking Alpha's Quant Rating on TScan Therapeutics Historical earnings data for TScan Therapeutics Financial information for TScan Therapeutics Recommended For You Comments More Trending News
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% PremiumGlobeNewswire
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley BankGlobeNewswire
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.MarketBeat
TCRX
Earnings
- 11/12/24 - Beat
TCRX
Sec Filings
- 12/30/24 - Form 4
- 12/26/24 - Form 8-K
- 12/26/24 - Form 424B5
- TCRX's page on the SEC website